# PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

> **NCT06290622** · PHASE1 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular

## Interventions

- **DRUG:** Retifanlimab, INCAGN02385, INCAGN02390

## Key facts

- **NCT ID:** NCT06290622
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator request to no longer pursue this study. Lack of support from drug company. This trial never opened. Withdrew IND.
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06290622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06290622, "PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06290622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*